WO2003000118A2 - Method for enhancing the effectiveness of cancer therapies - Google Patents

Method for enhancing the effectiveness of cancer therapies Download PDF

Info

Publication number
WO2003000118A2
WO2003000118A2 PCT/US2002/019885 US0219885W WO03000118A2 WO 2003000118 A2 WO2003000118 A2 WO 2003000118A2 US 0219885 W US0219885 W US 0219885W WO 03000118 A2 WO03000118 A2 WO 03000118A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
patient
administering
galectin
modified pectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/019885
Other languages
English (en)
French (fr)
Other versions
WO2003000118A3 (en
Inventor
Yang Chang
Vodek Sasek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlycoGenesys Inc
Original Assignee
GlycoGenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlycoGenesys Inc filed Critical GlycoGenesys Inc
Priority to MXPA03012021A priority Critical patent/MXPA03012021A/es
Priority to EP02749641A priority patent/EP1406639A4/en
Priority to BR0210550-0A priority patent/BR0210550A/pt
Priority to JP2003506572A priority patent/JP2004535430A/ja
Priority to CA002451841A priority patent/CA2451841A1/en
Priority to IL15946102A priority patent/IL159461A0/xx
Priority to AU2002320140A priority patent/AU2002320140B2/en
Publication of WO2003000118A2 publication Critical patent/WO2003000118A2/en
Publication of WO2003000118A3 publication Critical patent/WO2003000118A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Galectins comprise a family of proteins which are expressed by plant and animal cells and which bind ⁇ -galactoside sugars. These proteins can be found on cell surfaces, in cytoplasm, and in extracellular fluids. They have a molecular weight in the general range of 29-34 kD; they have an affinity for ⁇ - galactoside containing materials, and have been found to play a number of important roles in biological processes including cell migration, cell-cell adhesion, angiogenesis, cell fusion and other cell-cell interactions, as well as immune-based reactions and apoptosis. As such, the role of galectins is very strongly tied to cancer and other proliferative diseases.
  • the treatment being enhanced may comprise chemotherapy, radiation therapy, surgery and combinations thereof.
  • the method of the present invention comprises administering to a patient a therapeutically effective amount of a compound which binds to a galectin. This compound may be administered prior to, after, or concomitant with the other treatment.
  • U.S. Patent 5,895,784 the disclosure of which is incorporated herein by reference, describes modified pectin materials, techniques for their preparation, and use of the material as a treatment for various cancers.
  • the material of the '784 patent is described as being prepared by a pH based modification procedure in which the pectin is put into solution and exposed to a series of programmed changes in pH which results in the breakdown of the molecule to yield therapeutically effective modified pectin.
  • the material in the '784 patent is most preferably prepared from citrus pectin; although, it is to be understood that modified pectins may be prepared from pectin starting material obtained from other sources, such as apple pectin and the like.
  • a galectin binding therapeutic material is administered to a patient, in combination with conventional therapies such as surgery, radiation or chemotherapy.
  • the material is most preferably administered prior to the administration ofthe conventional therapy, so as to allow it sufficient time to interact with and bind to galectins in the tumor or in non-cancerous cells.
  • administration of the galectin binding therapeutic material may be continued while the other therapy is being administered and/or thereafter.
  • Administration of the galectin binding material may be made in a single dose, or in multiple doses.
  • administration of the therapeutic material is commenced at least several days prior to the conventional therapy, while in other instances, administration is begun either immediately before or at the time of the administration of the conventional therapy.
  • the carbohydrate material may be advantageously administered both before, during and after the therapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PCT/US2002/019885 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies Ceased WO2003000118A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MXPA03012021A MXPA03012021A (es) 2001-06-21 2002-06-21 Metodo para mejorar la efectividad de las terapias contra el cancer.
EP02749641A EP1406639A4 (en) 2001-06-21 2002-06-21 IMPROVING THE EFFECTIVENESS OF CANCER THERAPIES
BR0210550-0A BR0210550A (pt) 2001-06-21 2002-06-21 Método para realçar a eficácia de terapias contra o câncer
JP2003506572A JP2004535430A (ja) 2001-06-21 2002-06-21 癌治療の有効性を向上させる方法
CA002451841A CA2451841A1 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies
IL15946102A IL159461A0 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies
AU2002320140A AU2002320140B2 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29999101P 2001-06-21 2001-06-21
US60/299,991 2001-06-21
US10/176,235 2002-06-20
US10/176,235 US6680306B2 (en) 2001-06-21 2002-06-20 Method for enhancing the effectiveness of cancer therapies

Publications (2)

Publication Number Publication Date
WO2003000118A2 true WO2003000118A2 (en) 2003-01-03
WO2003000118A3 WO2003000118A3 (en) 2003-04-10

Family

ID=26872020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019885 Ceased WO2003000118A2 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies

Country Status (11)

Country Link
US (3) US6680306B2 (OSRAM)
EP (1) EP1406639A4 (OSRAM)
JP (1) JP2004535430A (OSRAM)
CN (1) CN100558367C (OSRAM)
AU (1) AU2002320140B2 (OSRAM)
BR (1) BR0210550A (OSRAM)
CA (1) CA2451841A1 (OSRAM)
CZ (1) CZ200487A3 (OSRAM)
IL (1) IL159461A0 (OSRAM)
MX (1) MXPA03012021A (OSRAM)
WO (1) WO2003000118A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522163A (ja) * 2003-04-07 2006-09-28 グリコジェネシス， インク． ガレクチンアンタゴニストの組成物と使用
US7893252B2 (en) 2003-09-08 2011-02-22 Pro-Pharmaceuticals, Inc. Selectively depolymerized galactomannan polysaccharide

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) * 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
JP2007531697A (ja) * 2003-07-11 2007-11-08 プロ−ファーマシューティカルズ，インコーポレイティド 疎水性薬剤のデリバリーのための組成物と方法
DE10335236B3 (de) * 2003-08-01 2005-02-24 Drägerwerk AG Messsystem für die Bestimmung der Konzentration von Propofol (2,6-Diisopropylphenol) im Atemstrom
WO2005037293A1 (en) * 2003-10-16 2005-04-28 Univ Monash Immunomodulating compositions and uses therefor
US20050282773A1 (en) * 2004-01-14 2005-12-22 Pro-Pharmaceuticals, Inc. Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
EP1765874A1 (en) 2004-03-26 2007-03-28 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
CN101146553A (zh) * 2005-03-23 2008-03-19 辉瑞产品公司 用于治疗癌症的抗-ctla4抗体和吲哚酮组合治疗
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
WO2009018447A2 (en) * 2007-07-31 2009-02-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
US8968740B2 (en) 2009-11-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
RU2545859C1 (ru) * 2011-12-08 2015-04-10 Исаак ЭЛИАС Уменьшение уровней галектина-3 посредством плазмафереза
AU2012363033B2 (en) * 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
WO2013184892A1 (en) 2012-06-06 2013-12-12 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
WO2014043708A1 (en) 2012-09-17 2014-03-20 Traber Peter G Method for enhancing specific immunotherapies in cancer treatment
ES2698101T3 (es) 2012-10-10 2019-01-31 Galectin Therapeutics Inc Compuestos de carbohidrato con restos de galactosa para el tratamiento de la nefropatía diabética y trastornos asociados
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
WO2015071910A1 (en) 2013-11-17 2015-05-21 Rdd Pharma Ltd. Methods for treating radiation induced gastrointestinal tract injury
CA3031691A1 (en) 2016-09-13 2018-03-22 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
AU2018265571B2 (en) 2017-05-12 2022-09-29 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
KR20210108414A (ko) 2018-12-25 2021-09-02 솔-겔 테크놀로지스 리미티드 Egfr 억제제를 포함하는 조성물에 의한 피부 장애 치료

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107222A (en) * 1870-09-13 Improvement in machines for tenoning window-sash
US5490991A (en) 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5843442A (en) 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5639737A (en) 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
US20020107222A1 (en) 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer
US5490911A (en) * 1993-11-26 1996-02-13 The United States Of America As Represented By The Department Of Energy Reactive multilayer synthesis of hard ceramic foils and films
US5498702A (en) * 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
WO1997033593A1 (en) * 1996-03-15 1997-09-18 Takara Shuzo Co., Ltd. A product of heat treatment of uronic acid, food, drink or drug including the product
US5831052A (en) * 1997-05-07 1998-11-03 Incyte Pharmaceuticals, Inc. New human translocation associated protein
CN1282218A (zh) * 1997-10-15 2001-01-31 波拉克斯生物药品 使用砷化合物治疗原发性及转移性肿瘤疾病的组合物及方法
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
US6500807B1 (en) * 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6274566B1 (en) * 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
EP1363673A2 (en) * 2000-09-25 2003-11-26 Pro-Pharmaceuticals, Inc. Compositions for reducing side effects in chemotherapeutic treatments
US20020104222A1 (en) * 2001-02-06 2002-08-08 Jay Larry Dean Knife for removing the hide of an animal and method therefor
US6645946B1 (en) * 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
ES2376739T3 (es) * 2001-03-27 2012-03-16 Galectin Therapeutics Inc. Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
US6982255B2 (en) * 2001-03-27 2006-01-03 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6914055B2 (en) * 2001-03-27 2005-07-05 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522163A (ja) * 2003-04-07 2006-09-28 グリコジェネシス， インク． ガレクチンアンタゴニストの組成物と使用
EP1980257A1 (en) 2003-04-07 2008-10-15 Prospect Therapeutics, Inc. Compositions and uses of galectin antagonists
US7893252B2 (en) 2003-09-08 2011-02-22 Pro-Pharmaceuticals, Inc. Selectively depolymerized galactomannan polysaccharide

Also Published As

Publication number Publication date
US20040023925A1 (en) 2004-02-05
EP1406639A4 (en) 2004-07-28
US20040043962A1 (en) 2004-03-04
EP1406639A2 (en) 2004-04-14
WO2003000118A3 (en) 2003-04-10
MXPA03012021A (es) 2004-06-03
US6680306B2 (en) 2004-01-20
CN100558367C (zh) 2009-11-11
CA2451841A1 (en) 2003-01-03
CN1543351A (zh) 2004-11-03
IL159461A0 (en) 2004-06-01
BR0210550A (pt) 2004-05-25
AU2002320140B2 (en) 2007-11-29
JP2004535430A (ja) 2004-11-25
CZ200487A3 (cs) 2004-10-13
US20030013681A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
US6680306B2 (en) Method for enhancing the effectiveness of cancer therapies
AU2002320140A1 (en) Method for enhancing the effectiveness of cancer therapies
Wang et al. Osthole induces cell cycle arrest and inhibits migration and invasion via PTEN/Akt pathways in osteosarcoma
Heist et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer
US20140148404A1 (en) Composition and uses of galectin antagonists
JP5484320B2 (ja) ナリンゲニンとナリンジンを形質転換成長因子−β１のシグナル経路阻害剤とする使用
Ma et al. Ferulic acid attenuates adhesion molecule expression in gamma-radiated human umbilical vascular endothelial cells
Tyczyńska et al. Treatment strategies of gastric cancer—Molecular targets for anti-angiogenic therapy: A state-of-the-art review
CN108186643B (zh) 一种具有协同抗骨肉瘤功效的药物组合物及其应用
WO2004091634A1 (en) Composition and uses of galectin antagonists
Park et al. Antiangiogenic effect of bile acid acylated heparin derivative
Mavromanoli et al. Antithrombotics and new interventions for venous thromboembolism: exploring possibilities beyond factor IIa and factor Xa inhibition
CA2451885A1 (en) Method and material for treating immune diseases
AU2012281131B2 (en) Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment
CN107137407B (zh) 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
WO2000056334A1 (en) Use of imino sugars for anti-tumor therapy
Jakobsson et al. Protamine and mast-cell-mediated angiogenesis in the rat
DE60030567D1 (de) Aus muskeln abstammenden wirkstoffe enthaltende zusammensetzung
Amagase et al. Epidermal growth factor receptor‐mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors
Hanson et al. Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme
US10328056B2 (en) Priming of pancreatic tumor cells and cancer stem cells to TRAIL-induced apoptosis
Uhlenbruck et al. Prevention of experimental liver metastases by D-galactose
KR102212699B1 (ko) 유방암 예방 또는 치료용 조성물
Sonwani When Anticancer Agents Are Applied to Adenocarcinoma Cells, Platelets Improve Their Survival Rate Medications: Mechanisms and Chemoresistance Implications
KR102065150B1 (ko) 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2451841

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 159461

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003506572

Country of ref document: JP

Ref document number: PA/a/2003/012021

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2227/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 530345

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002320140

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2004-87

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002749641

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028160037

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002749641

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2004-87

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2002320140

Country of ref document: AU

Date of ref document: 20020621

Kind code of ref document: B